Nuclear Medicine and Biology
Volume 34, Issue 4 , Pages 363-370 , May 2007

Radiolabeled high affinity peptidomimetic antagonist selectively targets αvβ3 receptor-positive tumor in mice

  • Beom-Su Jang

      Affiliations

    • Department of Nuclear Medicine, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
    • ,
  • Esther Lim

      Affiliations

    • Department of Radiology, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
    • ,
  • Seung Hee Park

      Affiliations

    • Department of Nuclear Medicine, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
    • ,
  • In Soo Shin

      Affiliations

    • Department of Nuclear Medicine, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
    • ,
  • S. Narasimhan Danthi

      Affiliations

    • Department of Radiology, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
    • ,
  • In Sook Hwang

      Affiliations

    • Department of Nuclear Medicine, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
    • ,
  • Nhat Le

      Affiliations

    • Department of Nuclear Medicine, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
    • ,
  • Sarah Yu

      Affiliations

    • Department of Nuclear Medicine, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
    • ,
  • Jianwu Xie

      Affiliations

    • Department of Radiology, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
    • ,
  • King C.P. Li

      Affiliations

    • Department of Radiology, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
    • Current address: Department of Radiology, The Methodist Hospital, 6565 Fannin Street, MB1-066 Houston, TX 77030, USA.
    • ,
  • Jorge A. Carrasquillo

      Affiliations

    • Department of Nuclear Medicine, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
    • Current address: Nuclear Medicine Service, Memorial Sloan-Kettering Cancer Center, Mailbox 77, 1275 York Avenue, New York, NY 10021, USA.
    • ,
  • Chang H. Paik

      Affiliations

    • Department of Nuclear Medicine, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
    • Corresponding Author InformationCorresponding author: Tel.: +1 301 496 1426; fax: +1 301 402 4548.

Received 8 November 2006 ,Revised 8 February 2007 ,Accepted 11 February 2007.

References 

  1. Takagi J, Springer TA. Integrin activation and structural rearrangement. Immunol Rev. 2002;186:141–163
  2. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1(1):27–31
  3. Stromblad S, Cheresh DA. Integrins, angiogenesis and vascular cell survival. Chem Biol. 1996;3(11):881–885
  4. Ruoslahti E, Pierschbacher MD. Arg-Gly-Asp: a versatile cell recognition signal. Cell. 1986;44(4):517–518
  5. Pasqualini R, Koivunen E, Ruoslahti E. Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat Biotechnol. 1997;15(6):542–546
  6. Haubner R, Wester HJ, Reuning U, Senekowitsch-Schmidtke R, Diefenbach B, Kessler H, et al. Radiolabeled αvβ3 integrin antagonists: a new class of tracers for tumor targeting. J Nucl Med. 1999;40(6):1061–1071
  7. van Hagen PM, Breeman WA, Bernard HF, Schaar M, Mooij CM, Srinivasan A, et al. Evaluation of a radiolabelled cyclic DTPA-RGD analogue for tumour imaging and radionuclide therapy. Int J Cancer. 2000;90(4):186–198
  8. Harris TD, Kalogeropoulos S, Nguyen T, Liu S, Bartis J, Ellars C, et al. Design, synthesis, and evaluation of radiolabeled integrin αvβ3 receptor antagonists for tumor imaging and radiotherapy. Cancer Biother Radiopharm. 2003;18(4):627–641
  9. Chen X, Park R, Tohme M, Shahinian AH, Bading JR, Conti PS. MicroPET and autoradiographic imaging of breast cancer αv-integrin expression using 18F- and 64Cu-labeled RGD peptide. Bioconjug Chem. 2004;15(1):41–49
  10. Haubner R, Bruchertseifer F, Bock M, Kessler H, Schwaiger M, Wester HJ. Synthesis and biological evaluation of a 99mTc-labelled cyclic RGD peptide for imaging the αvβ3 expression. Nuklearmedizin. 2004;43(1):26–32
  11. DeNardo SJ, Burke PA, Leigh BR, O'Donnell RT, Miers LA, Kroger LA, et al. Neovascular targeting with cyclic RGD peptide (cRGDf-ACHA) to enhance delivery of radioimmunotherapy. Cancer Biother Radiopharm. 2000;15(1):71–79
  12. Bernard B, Capello A, van Hagen M, Breeman W, Srinivasan A, Schmidt M, et al. Radiolabeled RGD-DTPA-Tyr3-octreotate for receptor-targeted radionuclide therapy. Cancer Biother Radiopharm. 2004;19(2):173–180
  13. Capello A, Krenning EP, Bernard BF, Breeman WA, van Hagen MP, de Jong M. Increased cell death after therapy with an Arg-Gly-Asp-linked somatostatin analog. J Nucl Med. 2004;45(10):1716–1720
  14. Janssen M, Frielink C, Dijkgraaf I, Oyen W, Edwards DS, Liu S, et al. Improved tumor targeting of radiolabeled RGD peptides using rapid dose fractionation. Cancer Biother Radiopharm. 2004;19(4):399–404
  15. Onthank DC, Liu S, Silva PJ, Barrett JA, Harris TD, Robinson SP, et al. 90Y and 111In complexes of a DOTA-conjugated integrin αvβ3 receptor antagonist: different but biologically equivalent. Bioconjug Chem. 2004;15(2):235–241
  16. Haubner R, Wester HJ, Burkhart F, Senekowitsch-Schmidtke R, Weber W, Goodman SL, et al. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med. 2001;42(2):326–336
  17. Chen X, Park R, Shahinian AH, Bading JR, Conti PS. Pharmacokinetics and tumor retention of 125I-labeled RGD peptide are improved by PEGylation. Nucl Med Biol. 2004;31(1):11–19
  18. Chen X, Park R, Hou Y, Khankaldyyan V, Gonzales-Gomez I, Tohme M, et al. MicroPET imaging of brain tumor angiogenesis with 18F-labeled PEGylated RGD peptide. Eur J Nucl Med Mol Imaging. 2004;31(8):1081–1089
  19. Chen X, Hou Y, Tohme M, Park R, Khankaldyyan V, Gonzales-Gomez I, et al. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor αvβ3-integrin expression. J Nucl Med. 2004;45(10):1776–1783
  20. Chen X, Liu S, Hou Y, Tohme M, Park R, Bading JR, et al. MicroPET imaging of breast cancer αv-integrin expression with 64Cu-labeled dimeric RGD peptides. Mol Imaging Biol. 2004;6(5):350–359
  21. Chen X, Sievers E, Hou Y, Park R, Tohme M, Bart R, et al. Integrin αvβ3-targeted imaging of lung cancer. Neoplasia. 2005;7(3):271–279
  22. Wu Y, Zhang X, Xiong Z, Cheng Z, Fisher DR, Liu S, et al. MicroPET imaging of glioma integrin αvβ3 expression using 64Cu-labeled tetrameric RGD peptide. J Nucl Med. 2005;46(10):1707–1718
  23. Hood JD, Bednarski M, Frausto R, Guccione S, Reisfeld RA, Xiang R, et al. Tumor regression by targeted gene delivery to the neovasculature. Science. 2002;296(5577):2404–2407
  24. Li L, Wartchow CA, Danthi SN, Shen Z, Dechene N, Pease J, et al. A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticles. Int J Radiat Oncol Biol Phys. 2004;58(4):1215–1227
  25. Burnett CA, Xie J, Quijano J, Shen Z, Hunter F, Bur M, et al. Synthesis, in vitro, and in vivo characterization of an integrin αvβ3-targeted molecular probe for optical imaging of tumor. Bioorg Med Chem. 2005;13(11):3763–3771
  26. Mogensen CE, Solling K. Studies on renal tubular protein reabsorption: partial and near complete inhibition by certain amino acids. Scand J Clin Lab Invest. 1977;37(6):477–486
  27. Behr TM, Sharkey RM, Juweid ME, Blumenthal RD, Dunn RM, Griffiths GL, et al. Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives. Cancer Res. 1995;55(17):3825–3834
  28. Kobayashi H, Yoo TM, Kim IS, Kim MK, Le N, Webber KO, et al. l-Lysine effectively blocks renal uptake of 125I- or 99mTc-labeled anti-Tac disulfide-stabilized Fv fragment. Cancer Res. 1996;56(16):3788–3795
  29. Camera L, Kinuya S, Garmestani K, Brechbiel MW, Wu C, Pai LH, et al. Comparative biodistribution of indium- and yttrium-labeled B3 monoclonal antibody conjugated to either 2-(p-SCN-Bz)-6-methyl-DTPA (1B4M-DTPA) or 2-(p-SCN-Bz)-1,4,7,10-tetraazacyclododecane tetraacetic acid (2B-DOTA). Eur J Nucl Med. 1994;21(7):640–646
  30. Camera L, Kinuya S, Garmestani K, Wu C, Brechbiel MW, Pai LH, et al. Evaluation of the serum stability and in vivo biodistribution of CHX-DTPA and other ligands for yttrium labeling of monoclonal antibodies. J Nucl Med. 1994;35(5):882–889
  31. Yao Z, Zhang M, Axworthy DB, Wong KJ, Garmestani K, Park L, et al. Radioimmunotherapy of A431 xenografted mice with pretargeted B3 antibody-streptavidin and 90Y-labeled 1,4,7,10-tetraazacyclododecane-N,N′,Nʺ,Nʺ′-tetraacetic acid (DOTA)-biotin. Cancer Res. 2002;62(20):5755–5760
  32. Park LS, Szajek LP, Wong KJ, Plascjak PS, Garmestani K, Googins S, et al. Semi-automated 86Y purification using a three-column system. Nucl Med Biol. 2004;31(2):297–301
  33. Yao Z, Zhang M, Garmestani K, Axworthy DB, Mallett RW, Fritzberg AR, et al. Pretargeted alpha emitting radioimmunotherapy using 213Bi 1,4,7,10-tetraazacyclododecane-N,N′,Nʺ,Nʺ′-tetraacetic acid-biotin. Clin Cancer Res. 2004;10(9):3137–3146
  34. Sato N, Hassan R, Axworthy DB, Wong KJ, Yu S, Theodore LJ, et al. Pretargeted radioimmunotherapy of mesothelin-expressing cancer using a tetravalent single-chain Fv-streptavidin fusion protein. J Nucl Med. 2005;46(7):1201–1209
  35. Park SH, Jang BS, Lim E, Bur M, Xie J, Le N, et al. Synthesis and biodistribution of 99mTc(CO)3-tridentate-labeled integrin antagonist in tumor bearing mice. J Labelled Compd Radiopharm. 2005;48(S1):S290
  36. Haubner R, Wester HJ, Weber WA, Mang C, Ziegler SI, Goodman SL, et al. Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 2001;61(5):1781–1785
  37. Poethko T, Schottelius M, Thumshirn G, Hersel U, Herz M, Henriksen G, et al. Two-step methodology for high-yield routine radiohalogenation of peptides: 18F-labeled RGD and octreotide analogs. J Nucl Med. 2004;45(5):892–902
  38. Li C, Wang W, Wu Q, Ke S, Houston J, Sevick-Muraca E, et al. Dual optical and nuclear imaging in human melanoma xenografts using a single targeted imaging probe. Nucl Med Biol. 2006;33(3):349–358
  39. Decristoforo C, Faintuch-Linkowski B, Rey A, von Guggenberg E, Rupprich M, Hernandez-Gonzales I, et al. [99mTc]HYNIC-RGD for imaging integrin alpha(v)beta(3) expression. Nucl Med Biol. 2006;33(8):945–952

PII: S0969-8051(07)00041-8

doi: 10.1016/j.nucmedbio.2007.02.002

Nuclear Medicine and Biology
Volume 34, Issue 4 , Pages 363-370 , May 2007

Article Tools

* Image Usage & Resolution